595-33-5 Usage
Description
Megestrol Acetate is the acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. It is frequently used in the treatment of patients with metastatic breast cancer. It is generally well tolerated, except that it may cause undesirable weight gain. Subsequently, it was shown that megestrol acetate produced weight gain in a variety of cachectic cancer patients. Significant reduction inserum levels of IL-1a and b,IL-2,IL-6, and TNF-o were observed in cancer patientstreated with megestrol acetate which may bear on the mechanism of improved appetite and body weight gain.It has also been postulated that the effect is, at least in part,mediated by NPY,a potent central appetite stimulant.
Chemical Properties
Crystalline Solid
Originator
Megestat,Bristol,W. Germany,1964
Uses
Different sources of media describe the Uses of 595-33-5 differently. You can refer to the following data:
1. Megestrol acetate USP (Megace) is used to treat Carcinoma of the breast or endorometrium.
2. Megestrol acetate (Megace), a semi-synthetic progestational steroid, is the most effective known appetite stimulant at present. Previously used in patients with cancer and acquired immunodeficiency syndrome, only a few studies have considered the applicability of this drug in malnourished older persons. Megestrol acetate is useful if profound anorexia is the main manifestation of cachexia and if expected survival is weeks to months. Megace has been shown to significantly increase appetite, but not survival. In patients with a shorter predicted survival, a brief course of corticosteroids may be useful to stimulate appetite and have positive effects on nausea, pain, and asthenia.
Definition
ChEBI: Megestrol acetate is a steroid ester resulting from the formal condensation of the hydroxy group of megestrol with the carboxy group of acetic acid. It is an appetite stimulant used for the treatment of anorexia and cachexia. Also used for birth control and for the treatment of breast cancer. It has a role as an antineoplastic agent, an appetite enhancer, a contraceptive drug, a progestin and a synthetic oral contraceptive. It is a steroid ester, an acetate ester, a 20-oxo steroid and a 3-oxo-Delta(4) steroid. It derives from a megestrol.
Manufacturing Process
The following preparation is given in US Patent 3,356,573. 17α-Acetoxy-3βhydroxy-6-methylpregn-5-ene-20-one (1 g), aluminum tert-butoxide (1 g) and p-benzoquinone (6 g) were dissolved in dry benzene (100 ml) and the mixture was heated under reflux for 30 minutes. The reaction mixture was cooled and washed with potassium hydroxide solution until the benzene layer was colorless. The benzene was washed with water, dried and evaporated to dryness under reduced pressure. The residue crystallized from aqueous methanol to give 17α-acetoxy-6-methylpregna-4,6-diene-3,20-dione, needles, MP 214° to 216°C.
Brand name
Megace (Bristol-Myers Squibb); Megace (Par).
Therapeutic Function
Cancer chemotherapy
General Description
Megestrol acetate, 17-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate(Megace), is a progestin used primarily for the palliativemanagement of recurrent, inoperable, or metastatic endometrialor breast carcinoma. Megestrol acetate has also beenindicated for appetite enhancement in patients with AIDS.The biochemical basis for this use of megestrol is unclear.
Clinical Use
Progestin activity is further enhanced when a double bond is introduced between positions 6 and 7, as is found in megestrol
acetate. Megestrol is used primarily in the treatment of breast and endometrial carcinomas and in postmenopausal
women with advanced hormone-dependent carcinoma.
Safety Profile
Suspected carcinogen
with experimental carcinogenic and
teratogenic data. Poison by intravenous
route. Human reproductive effects bp
ingestion and implant routes: effects on
ovaries and fallopian tubes, menstrual cycle
changes, and female fertility index changes.
Mutation data reported. Experimental
reproductive effects. When heated to
decomposition it emits acrid smoke and
irritating fumes. An FDA proprietary drug
used to treat endometriosis and breast
cancer. A steroid.
Veterinary Drugs and Treatments
Megestrol acetate (Ovaban?—Schering) is approved by FDA for use
in dogs only for the postponement of estrus and the alleviation of
false pregnancy. In male dogs, it has been used for benign prostatic
hypertrophy. It is used clinically for many dermatologic and behavior-
related conditions, primarily in the cat. See the Dosage section
for specific indications and dosages for both dogs and cats.
Megestrol acetate is indicated in humans for the palliative treatment
of advanced carcinoma of the breast or endometrium.
Drug interactions
Potentially hazardous interactions with other drugs
Antibacterials: metabolism of progestogens
accelerated by griseofulvin and rifamycins.
Anticoagulants: progestogens antagonise
anticoagulant effect of phenindione; may enhance or
reduce anticoagulant effect of coumarins.
Antiepileptics: metabolism accelerated by
carbamazepine, eslicarbazepine, fosphenytoin,
oxcarbazepine, phenobarbital, phenytoin, primidone,
rufinamide and topiramate; concentration of
lamotrigine reduced; concentration reduced by high
dose perampanel.
Antivirals: metabolism accelerated by nevirapine.
Ciclosporin: progestogens inhibit metabolism of
ciclosporin (increased plasma concentration).
Dopaminergics: concentration of selegiline increased
- avoid.
Metabolism
Less than 10% of an oral dose undergoes metabolism. Several major
metabolites appear in the urine (e.g., 2-hydroxy and 6-hydroxymethyl megestrol and their glucuronide conjugates).
references
[1] zhang k1, chow pk. the effect of megestrol acetate on growth of hepg2 cells in vitro and in vivo. clin cancer res. 2004 aug 1; 10(15):5226-32.
Check Digit Verification of cas no
The CAS Registry Mumber 595-33-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,9 and 5 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 595-33:
(5*5)+(4*9)+(3*5)+(2*3)+(1*3)=85
85 % 10 = 5
So 595-33-5 is a valid CAS Registry Number.
InChI:InChI=1/C23H30O4/c1-14(24)23(27-15(2)25)12-9-20-18-6-5-16-13-17(26)7-10-21(16,3)19(18)8-11-22(20,23)4/h5-6,13,18-20H,7-12H2,1-4H3/t18-,19+,20+,21+,22+,23+/m1/s1
595-33-5Relevant articles and documents
The preparation method of the megestrol (by machine translation)
-
Paragraph 0009; 0012; 0014; 0016, (2018/01/13)
Megestrol preparation method, in order to 6 - keto - 17 a - acetoxy progesterone as raw material, the raw material in the organic solvent, in the original carboxylic acid triethyl ester existence under, with the glycol alkyd catalytic reaction double-[...]; then double [...] in the organic solvent, deprotecting reagent Grignard reaction, after the reaction in under the action of the strong acid, standard hydrolysis, at the same time deprotected, dehydration, by a two-step reaction to synthesize a megestrol crude; crude to decolorize with active carbon crystallization to, be a megestrol product, HPLC content 99.0 - 99.5%, melting point 213 - 220 °C, the weight of the two-step synthesis of the total yield of 80 - 85%. The invention relative to the traditional method, short synthetic route, the process operation is simple, production economy and environmental protection, the total synthesis than the traditional method to improve the yield of 30% or more, the production cost is reduced 30 - 35%; used in the process of recovering the solvent can be recycled, not only economic, environmental protection, and is favorable for industrial production. (by machine translation)
Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
-
, (2010/05/13)
Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers.
Process for the preparation of 6-methyl-Δ4,6 -3-keto steroids
-
, (2008/06/13)
A process for preparing 6-methyl-Δ4,6 -3-keto steroids of the formula STR1 comprises reacting a corresponding Δ4 -3-keto steroid with methoxymethyl acetate (CH3 --O--CH2 --OAc) in an inert solvent at temperatures above room temperature in the presence of an alkali metal acetate.
